$MBRX
Moleculin Biotech, Inc.

2016 Q3 Form 10-Q Financial Statement

#000114420416119213 Filed on August 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $920.0K $620.0K
YoY Change
% of Gross Profit
Research & Development $497.0K $105.0K
YoY Change 1193.97%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K
YoY Change
% of Gross Profit
Operating Expenses $1.422M $724.0K
YoY Change 538.38%
Operating Profit -$1.422M -$724.0K
YoY Change 538.38%
Interest Expense $10.00K $15.00K
YoY Change 540.2%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.430M -$740.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.432M -$739.0K
YoY Change 538.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$740.9K -$493.3K
COMMON SHARES
Basic Shares Outstanding 11.25M shares 11.23M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.180M $7.240M
YoY Change
Cash & Equivalents $6.184M $7.245M
Short-Term Investments
Other Short-Term Assets $240.0K $320.0K
YoY Change
Inventory
Prepaid Expenses $244.9K $315.1K
Receivables
Other Receivables
Total Short-Term Assets $6.429M $7.560M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $16.35K $7.168K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.15M $11.67M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $6.429M $7.560M
Total Long-Term Assets $11.15M $11.67M
Total Assets $17.57M $19.23M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $980.0K $970.0K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K $430.0K
YoY Change
Total Short-Term Liabilities $1.280M $1.403M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $50.00K $600.0K
YoY Change
Other Long-Term Liabilities $50.00K $600.0K
YoY Change
Total Long-Term Liabilities $50.00K $600.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.280M $1.403M
Total Long-Term Liabilities $50.00K $600.0K
Total Liabilities $1.330M $2.003M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$3.251M -$2.076M
YoY Change
Common Stock $19.50M $19.31M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.24M $17.23M
YoY Change
Total Liabilities & Shareholders Equity $17.57M $19.23M
YoY Change

Cashflow Statement

Concept 2016 Q3 2016 Q2
OPERATING ACTIVITIES
Net Income -$1.432M -$739.0K
YoY Change 538.39%
Depreciation, Depletion And Amortization $1.000K $1.000K
YoY Change
Cash From Operating Activities -$950.0K -$1.360M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$100.0K $30.00K
YoY Change
Cash From Investing Activities -$110.0K $30.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 8.310M
YoY Change
NET CHANGE
Cash From Operating Activities -950.0K -1.360M
Cash From Investing Activities -110.0K 30.00K
Cash From Financing Activities 0.000 8.310M
Net Change In Cash -1.060M 6.980M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$950.0K -$1.360M
Capital Expenditures -$10.00K
Free Cash Flow -$940.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7244684 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28091 USD
CY2016Q2 us-gaap Assets
Assets
19233399 USD
CY2015Q4 us-gaap Assets
Assets
28091 USD
CY2016Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
721103 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
322790 USD
CY2016Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
431644 USD
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
450000 USD
CY2016Q2 us-gaap Liabilities
Liabilities
2002747 USD
CY2015Q4 us-gaap Liabilities
Liabilities
772790 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
11255 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
6661 USD
CY2016Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
3000 USD
CY2015Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
3000 USD
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19298614 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
0 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2076217 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-748360 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
17230652 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-744699 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19233399 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28091 USD
us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
376728 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
923572 USD
us-gaap Operating Expenses
OperatingExpenses
1300952 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1300952 USD
us-gaap Interest Expense
InterestExpense
26905 USD
us-gaap Net Income Loss
NetIncomeLoss
-1327857 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7796782 shares
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
361728 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
618001 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
980381 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-980381 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
15235 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-995616 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8875173 shares
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
469939 USD
us-gaap Share Based Compensation
ShareBasedCompensation
161496 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-421938 USD
dei Entity Registrant Name
EntityRegistrantName
Moleculin Biotech, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001659617
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1645901 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
362 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8862132 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7216593 USD
us-gaap Interest Paid
InterestPaid
47951 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2016Q2 mbrx Operating Loss Carryforwards Expiration Period
OperatingLossCarryforwardsExpirationPeriod
2035
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2025-12-05
mbrx Debt Instrument Convertible Number Of Common Shares
DebtInstrumentConvertibleNumberOfCommonShares
2691803 shares
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Trading Symbol
TradingSymbol
MBRX
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11254756 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates in Financial Statement Presentation -</b> The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
256889 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
850000 USD
CY2016Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1166503 shares
CY2015Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
0 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1402747 USD
CY2016Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
183356 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
772790 USD
CY2016Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1700000 USD
CY2016Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
315143 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
7559827 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
28091 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7168 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2016Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11666404 USD
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
600000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2016Q2 mbrx Class Of Warrant Or Right Period From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodFromWhichWarrantsOrRightsExercisable
P5Y
CY2016Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
107802 shares
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.50
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11254756 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6661000 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11254756 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6661000 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
234296 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
702888 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
652 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
652 USD
mbrx Common Stock Lockup And Leakout Agreements Description
CommonStockLockupAndLeakoutAgreementsDescription
These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share.
CY2016Q2 us-gaap Interest Payable Current
InterestPayableCurrent
17699 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
315143 USD
CY2016Q2 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
750000 USD
mbrx Debt Conversion Converted Instrument Common Stock Shares Issued Trading Restrictions Description
DebtConversionConvertedInstrumentCommonStockSharesIssuedTradingRestrictionsDescription
(a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales.
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
362 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9167071 USD
us-gaap Stock Issued1
StockIssued1
3774000 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
201055 USD
mbrx Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Value Of Shares Issued
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationValueOfSharesIssued
5999586 USD
CY2016Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-1039059 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-1558839 USD
CY2016Q2 mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.11
mbrx Business Acquisition Pro Forma Earnings Per Share Basic And Diluted
BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted
-0.18
CY2016Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6744684 USD
CY2016Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
1000000 USD
CY2016Q2 mbrx Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
9215150 shares
mbrx Business Acquisition Pro Forma Weighted Average Number Of Shares Outstanding Basic And Diluted
BusinessAcquisitionProFormaWeightedAverageNumberOfSharesOutstandingBasicAndDiluted
8466736 shares
CY2016Q2 mbrx Business Acquistion Pro Forma Operating Expenses
BusinessAcquistionProFormaOperatingExpenses
-1018579 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
165000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2016Q2 mbrx Shares Authorized
SharesAuthorized
80000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
mbrx Business Acquistion Pro Forma Operating Expenses
BusinessAcquistionProFormaOperatingExpenses
-1446394 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
256889 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
0 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11666404 USD
CY2016Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
250000 USD
CY2015Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0 USD

Files In Submission

Name View Source Status
0001144204-16-119213-index-headers.html Edgar Link pending
0001144204-16-119213-index.html Edgar Link pending
0001144204-16-119213.txt Edgar Link pending
0001144204-16-119213-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbrx-20160630.xml Edgar Link completed
mbrx-20160630.xsd Edgar Link pending
mbrx-20160630_cal.xml Edgar Link unprocessable
mbrx-20160630_def.xml Edgar Link unprocessable
mbrx-20160630_lab.xml Edgar Link unprocessable
mbrx-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v445890_10q.htm Edgar Link pending
v445890_ex31-1.htm Edgar Link pending
v445890_ex31-2.htm Edgar Link pending
v445890_ex32-1.htm Edgar Link pending
v445890_ex32-2.htm Edgar Link pending